ing investors, provides further validation of Divergence's revolutionary technology and the rapid advancements of our projects in parasite control," said Derek K. Rapp, Chief Executive Officer of Divergence. "Through our internal programs and corporate alliances in crop protection and animal health, Divergence is committed to the development of parasite control products for higher yielding agriculture and healthier people and animals. Upon the completion of this financing, Ronald L. Meeusen, Ph.D., Partner of Midpoint Food & Ag Fund, LP, will join the Divergence Board of Directors. Dr. Meeusen brings to Divergence more than 25 years of corporate experience in agricultural biotechnology. "There is tremendous value in the cutting-edge science of Divergence," said Dr. Meeusen. "As the first company in our investment portfolio, Divergence exemplifies our goal to invest in companies that can enable environmentally sustainable agriculture and offer promise for human and animal wellness."
With the addition of Dr. Meeusen, the Board of Directors of Divergence stands at seven people - Stanford J. Goldblatt, Partner and Head of the Private Equity Practice at Winston & Strawn; James P. McCarter, M.D., Ph.D., President and Chief Scientific Officer of Divergence; John W. McCarter, Jr., President and CEO of the Field Museum in Chicago; Ronald L. Meeusen, Ph.D., Partner of MidPoint Food and Ag Fund, LP; Ilya B. Nykin, Managing Director of Prolog Ventures; Derek K. Rapp, Chief Executive Officer of Divergence; and Mark W. Wong, President and CEO of Agrivida, Inc.
Divergence, Inc., a world leader in the application of genomics and informatics to agriculture and infectious disease, discovers and develops products for the safe and effective control of parasites. The company's initial focus is on parasitic nematodes, devastating unseen pests that cause billions of dollars in crop loss annually and wides
Page: 1 2 3 Related biology technology :1
Copyright©2009 Vocus, Inc.
All rights reserved
. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.2
. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)3
. JMAR Technologies Raises Awareness of BioSentry -- A High Tech Counter to Bioterrorism4
. Anacor Raises $50 Million in Equity Financing5
. MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile6
. Sensorin Raises Equity Financing to Launch Novel Industrial Sensing Venture7
. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth8
. Vista Partners Updates Coverage on Arana Therapeutics (ASX: AAH; AIM: AAHx), Raises Target Price to AU$1.659
. Ameristar National Charity Golf Classic Raises More Than $1.1 Million for Buoniconti Fund to Cure Paralysis and Christopher & Dana Reeve Foundation10
. China Sky One Medical, Inc. Raises Guidance for 2008 Revenue and Net Income11
. MacroGenics Raises $25M in Series D-2 Financing